CurveBeam AI (ASX:CVB) ROCE %: -35.19% (As of Dec. 2025)


What is CurveBeam AI ROCE %?

CurveBeam AI ASX:CVB -6.67% ROCE % is -35.19% as of Dec. 2025. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CurveBeam AI's annualized ROCE % for the quarter that ended in Dec. 2025 was -35.19%.

CurveBeam AI  (ASX:CVB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CurveBeam AI ROCE % Related Terms

CurveBeam AI ROCE % Historical Data

* Premium members only.

The historical data trend for CurveBeam AI's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CurveBeam AI ROCE % Chart

CurveBeam AI Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
0.00 0.00 -201.72 -55.22 -29.93

CurveBeam AI Semi-Annual Data
Jun21 Dec21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only -61.83 -29.83 -35.94 -21.68 -35.19

CurveBeam AI ROCE % Calculation

CurveBeam AI's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-16.152/( ( (63.329 - 8.166) + (60.984 - 8.212) )/ 2 )
=-16.152/( (55.163+52.772)/ 2 )
=-16.152/53.9675
=-29.93 %

CurveBeam AI's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-18.82/( ( (60.984 - 8.212) + (61.762 - 7.566) )/ 2 )
=-18.82/( ( 52.772 + 54.196 )/ 2 )
=-18.82/53.484
=-35.19 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -35.19% mean?
CurveBeam AI (ASX:CVB) has a ROCE % of -35.19% as of Dec. 2025.
Is CurveBeam AI's ROCE % too high?
CurveBeam AI's current ROCE % is -35.19%.
How does CurveBeam AI's ROCE % compare to ABT and SYK?
CurveBeam AI's ROCE % of -35.19% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current ROCE % is -35.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current ROCE % of -35.19%. The current ROCE % is -35.19%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current ROCE % is -35.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CurveBeam AI Business Description

Address 10 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.